Wire · opportunities
Teva wins FDA approval for monthly schizophrenia injection Weltruza
◆ Sectors
◆ Geography
◆ Source
◆ Verified
Fusion42 · 10 October 2026 · Fusion42 review
Teva received FDA approval for Weltruza, a once-monthly injection for adults with schizophrenia, marking their second US-approved product from a partnership with Medincell. The drug uses long-acting injectable technology designed to improve medication adherence in chronic psychiatric conditions.
This Wire brief sits within Fusion42's coverage of Biotech, and 14 sources have reported it between 9 Oct 2026 and 10 Oct 2026.
◆ ◆ The Wire takeaway
The FDA's approval of a monthly schizophrenia injection opens US market access for long-acting psychiatric treatments. You should explore partnerships in this space or consider how this approval shifts adherence solutions your product could compete with.
◆ Coverage
14 sources · first reported 9 Oct 2026 · latest 10 Oct 2026
◆ Topics